Navigation Links
S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
Date:5/4/2010

r cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors.ONX 0801, a targeted alpha-folate inhibitor, is currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

Forward-Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of SB1518 (ONX 0803) and SB1578 (ONX 0805).  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 20
'/>"/>

SOURCE S*BIO Pte Ltd; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
2. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
3. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
4. S*BIO Completes US$26 Million Equity Financing
5. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
6. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
7. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
8. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
9. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
10. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
11. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Xencor, Inc. (NASDAQ: XNCR ... antibodies for the treatment of autoimmune diseases, asthma ... appointment of Debra Zack , M.D., Ph.D., ... Lloyd Rowland , senior vice president, chief ... "Debra,s expertise in biologics clinical development and medical ...
(Date:9/2/2014)... Winston-Salem, NC and Rocky Mount, NC (PRWEB) September 02, ... (PMG) announced today the establishment of its 11th clinical ... 1, PMG Research has assumed ownership and operation of ... in Rocky Mount, NC, further expanding PMG’s presence in ... to an additional 130,000 patients. For the patients in ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue: India Solid Waste Management Vehicles ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... governing bodies responsible for complete handling and regulation ... average, around 135,000 MT solid waste is generated ...
(Date:8/31/2014)... Available spectra is similar for all L-series products ... a wide range of plants. The spectra is ... and pending wide spectrum technology. The single chip ... in contrast to growth spectra made from monochromatic ... large variety of differently sized and shaped growing ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... 3 Ikaria Holdings, Inc., a fully,integrated critical ... CEO, David Shaw, will present at the 26th ... at 3:00 p.m., PST. The,conference will be held ... in San,Francisco., About Ikaria Holdings, Inc., ...
... than 500,000 Total Prescriptions Have Been Dispensed for ... ... 3 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the ... from the U.S. Food and Drug,Administration (FDA) for three additional ...
... Jan. 3 Neogen Corporation,(Nasdaq: NEOG ) announced ... FY 2008, which ended Nov. 30, increased 34% from ... split, net income in the,quarter rose to $0.22 per ... net income of $3,254,000 set another quarterly,record for the ...
Cached Biology Technology:FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 2FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 3FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 4FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 5Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5
(Date:9/1/2014)... decisions of the Nomenclature Section of the XVIII International ... 2011. This meeting is held every six years and ... rules for naming algae, fungi and plants get together ... the organisms they study. This is the primary product ... algae, fungi, and plants, which was published in 2012. ...
(Date:8/31/2014)... fast and accurate tool to diagnose tuberculosis in ... developed test (TAM-TB assay) is the first reliable ... The test features excellent specificity, a similar sensitivity ... a blood test. The promising findings are a ... children, particularly in tuberculosis-endemic regions. , The study ...
(Date:8/31/2014)... of the greatest challenges in modern medicine is developing ... with minimal toxicity and side-effects to the patient. Such ... the drug molecule. Ideally, the drug should have a ... so that it binds it with high specificity. Publishing ... a synthetic amino acid that can impact the 3D ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2New tuberculosis blood test in children is reliable and highly specific 2A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3
... WORCESTER, Mass. Orthopedic surgeons are often hamstrung ... bone injuries resulting from trauma, aging or cancer. Conventional ... or brittle ceramics, and cannot readily conform to the ... in addition, they often require metallic fixation devices that ...
... Swiss needle cast epidemic in Douglas-fir forests of the coastal ... over at least the past 100 years, and is probably ... and a warmer climate, new research concludes. Scientists in ... found that this disease, which is affecting hundreds of thousands ...
... the University of Alabama at Birmingham (UAB) have been ... Scholarship and Excellence in Education Foundation. Atbin Doroodchi, ... Biology and Mathematics. He has a 3.95 grade-point average ... Honors Program. Doroodchi is an undergraduate researcher in the ...
Cached Biology News:Smart orthopedic implants and self-fitting tissue scaffolding created by UMMS researchers 2Forest epidemic is unprecedented phenomenon, still getting worse 2Forest epidemic is unprecedented phenomenon, still getting worse 3Forest epidemic is unprecedented phenomenon, still getting worse 43 UAB students awarded prestigious Goldwater scholarships 2
... Clone/PAD: ZMD.358. Immunogen: Synthetic ... region of human mouse and ... with human and mouse LRP5 ... (positive controls: mouse LRP5-pSEC-tag-transfected 293T ...
MarrowMAX Bone Marrow Medium...
... recognizes murine IRF7 protein, and ... related IRF proteins. Reactivity of ... protein was confirmed by western ... cells transfected with IRF7. Reactivity ...
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
Biology Products: